Justice Department Says Clean Harbors Will Clean Up Louisiana Superfund Site
By Matt Walker
Clean Harbors and two of its subsidiaries will clean up decades-old contamination at the Devil's Swamp Lake Superfund Site after reaching an agreement with the Justice Department and Environmental Protection Agency.
The cleanup is estimated to cost over $3 million, the department said on Thursday. Clean Harbor and its subsidiaries, Clean Harbors Baton Rouge LLC and Baton Rouge Disposal LLC, are also required to reimburse over $2 million in costs incurred by the U.S. in responding to the contamination at Devil's Swamp Lake.
The companies will also pay the U.S. for all costs it spends in the future for that purpose.
Devil's Swamp Lake is contaminated with polychlorinated biphenyls (PCBs), chemicals that build up over time and have been linked to cancer, according to the department. Due in part to PCB levels, Louisiana state agencies have issued advisories warning the public not to swim in or eat fish caught in Devil's Swamp Lake.
The Devil's Swamp Lake Superfund Site is located in East Baton Rouge Parish in Louisiana.
Write to Matt Walker at matthew.walker@dowjones.com
(END) Dow Jones Newswires
August 22, 2024 18:50 ET (22:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks